CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 20 target
Drug / intervention
4SCAR-PSMA +1 moregenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03185468
NCT03185468Phase 1RecruitingOn Track
CompareCT.gov

Intervention of Advanced or Metastatic Urothelial Bladder Cancer by 4SCAR-T Cell Therapies

Shenzhen Geno-Immune Medical Institute·interventional·Posted Jun 14, 2017·Updated Jun 23, 2026

In Brief

A Phase 1 clinical trial evaluating 4SCAR-PSMA and 4SCAR-FRa for Bladder Cancer and Urothelial Carcinoma Bladder. Currently recruiting, targeting 20 participants across 1 site.

Detailed Summary

This is a Phase I/II and multicenter study designed to evaluate the efficacy and safety of 4SCAR-T cells in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have no further treatment available.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer, Urothelial Carcinoma Bladder
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
2018201920202021202220232024202520262027202820292030
First PostedJun 14, 2017
Enrollment StartAug 1, 2025
Primary CompletionDec 31, 2028
Study CompletionDec 31, 2029
TodayJul 1, 2026
Enrollment to primary: 3.4 yearsPosted 9.0 years agoPrimary completion in 2.5 years

Arms & Interventions

4SCAR-PSMAexperimental

4SCAR PSMA-modified T cells can recognize and kill tumor cells through the recognize of PSMA .This study will evaluate the side effects and effective doses of 4SCAR-PSMA T cells in treating refractory and recurrent solid tumors.

Genetic: 4SCAR-PSMA
4SCAR-FRaexperimental

4SCAR FRa-modified T cells can recognize and kill tumor cells through the recognize of FRa .This study will evaluate the side effects and effective doses of 4SCAR-FRa T cells in treating refractory and recurrent solid tumors.

Genetic: 4SCAR-FRa

Interventions

4SCAR-PSMAgenetic

PSMA-specific 4th Generation CART

4SCAR-FRagenetic

FRa-specific 4th Generation CART